Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach
Stewart‐Merrill, Suzanne B., Thompson, R. Houston, Boorjian, Stephen A. , Psutka, Sarah P. , Lohse, Christine M. , Cheville, John C. , Leibovich, Bradley C. , Frank, Igor, Psutka, Sarah P

Mayo Clinic

Journal of Clinical Oncology | September 8, 2015 | Volume: 33 | Issue: 35 | Pages: 4151-4157

10.1200/jco.2015.61.8009 | PMID 26351352 Get It

Purpose The appropriate duration of surveillance for renal cell carcinoma (RCC) after radical or partial nephrectomy remains unknown, and evidence to support current guidelines are lacking. Herein, we provide an approach to surveillance that balances the risk of recurrence versus the risk of non-RCC death. Patients and Methods We identified 2,511 patients who underwent surgery for M0 RCC between 1990 and 2008. Patients were stratified for analysis by pathologic stage (pT1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN1), relapse location (abdomen, chest, bone, and other), age (< 50, 50 to 59, 60 to 69, 70-79 and ≥ 80 years), and Charlson comorbidity index (CCI; ≤ 1 and ≥ 2). Risks of disease recurrence and non-RCC death were estimated by using parametric models for time-to-failure with Weibull distributions. Surveillance duration was estimated at the point when the risk of non-RCC death exceeded the risk of recurrence. Results At a median follow-up of 9.0 years (interquartile range, 6.4 to 12.7 years), a total of 676 patients developed recurrence. By using a competing-risk model, vastly different surveillance durations were appreciated. Specifically, among patients with pT1Nx-0 disease and a CCI ≤ 1, risk of non-RCC death exceeded that of abdominal recurrence risk at 6 months in patients age 80 years and older but failed to do so for greater than 20 years in patients younger than age 50 years. For patients with pT1Nx-0 disease but a CCI ≥ 2, the risk of non-RCC death exceeded that of abdominal recurrence risk already at 30 days after surgery, regardless of patient age. Conclusion We present an individualized approach to RCC surveillance that bases the duration of follow-up on the interplay between competing risk factors of recurrence and non-RCC death. This strategy may improve the balance between the derived benefit from surveillance and medical resource allocation.
Response to the Letter by Pauwels, et al
Hawkes, Colin P. , Schnellbacher, Sarah, Singh, Rajat , Levine, Michael A. , Levine, M A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 4, 2015 | Volume: 100 | Issue: 9 | Pages: L84-L85

10.1210/jc.2015-3007 | PMID 26339746 Get It

The Impact of Pelvic Floor and Lower Gastrointestinal Symptoms on Quality of Life in Women With Systemic Sclerosis
Umar, Sarah B. , Griffing, Leroy, Garcia, Heidi, Foxx–Orenstein, Amy E., DiBaise, John K. , Crowell, Michael D.

Mayo Clinic

Journal of Clinical Gastroenterology | September 1, 2015 | Volume: 50 | Issue: 6 | Pages: e55-e59

10.1097/mcg.0000000000000405 | PMID 26325189 Get It

Background: Systemic sclerosis (SSc) patients with gastrointestinal (GI) involvement have a lower quality of life (QoL) and while the impact of upper GI symptoms on QoL in SSc patients has been described few data exist on the presence and impact of lower gastrointestinal (LGI) and pelvic floor symptoms in SSc. Our goal was to assess the prevalence of these symptoms in women with SSc and evaluate their impact on QoL. A secondary hypothesis was that the impact of LGI symptoms on QoL is mediated by depression. Study: Women with SSc (n=175) attending an outpatient scleroderma clinic completed multiple validated questionnaires. Pelvic floor and LGI symptoms included fecal incontinence (FI), urinary incontinence (UI), dual incontinence (DI), chronic constipation, diarrhea, and pelvic pain. The Student t tests adjusted for multiple comparisons were used to evaluate group differences at the 0.05 level. Results: Complete data were available for 160 women. FI was reported by 65, UI by 64, DI by 40, chronic constipation by 94, diarrhea by 82, and pelvic pain by 35 of SSc patients. Overall QoL was reduced in SSc patients with FI (0.96 vs. 0.63; P=0.007), UI (0.96 vs. 0.65; P=0.01), DI (1.11 vs. 0.67; P=0.002), and pelvic pain (1.01 vs. 0.70; P=0.04). Antidepressant use was reported by 26%. The negative impact on QoL in patients with pelvic floor symptoms was partially mediated by depression. Conclusions: Women with SSc suffer from an increased prevalence of LGI and pelvic floor symptoms including FI, UI, diarrhea, constipation, and pelvic pain and this effect seems to be partially mediated by depression.
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Gradishar, William J. , Sparano, Joseph A. , Chuang, Ellen, Northfelt, Donald W. , Schwartz, Gary N. , Youssoufian, Hagop , Tang, Shande, Novosiadly, Ruslan D., Forest, Amélie, Nguyen, Tuan S., Cosaert, Jan , Grebennik, Dmitri, Haluska, Paul , Yardley, Denise Aysel , Layman, Rachel M. , Sparano, Joseph A

Mayo Clinic

Clinical Cancer Research | August 31, 2015 | Volume: 22 | Issue: 2 | Pages: 301-309

10.1158/1078-0432.ccr-15-0588 | PMID 26324738 Get It

Abstract Purpose: This phase II trial evaluated the efficacy and safety of cixutumumab, a human anti–insulin-like growth factor receptor 1 (IGF-1R) monoclonal IgG1 antibody, and explored potential biomarkers in postmenopausal women with hormone receptor–positive breast cancer. Experimental Design: Patients with hormone receptor–positive breast cancer that progressed on antiestrogen therapy received (2:1 randomization) cixutumumab 10 mg/kg and the same antiestrogen (arm A) or cixutumumab alone (arm B) every 2 weeks (q2w). Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and safety. Correlative analyses of IGF-1R, total insulin receptor (IR), and IR isoforms A (IR-A) and B (IR-B) expression in tumor tissue were explored. Results: Ninety-three patients were randomized (arm A, n = 62; arm B, n = 31). Median PFS was 2.0 and 3.1 months for arm A and arm B, respectively. Secondary efficacy measures were similar between the arms. Overall, cixutumumab was well tolerated. IGF-1R expression was not associated with clinical outcomes. Regardless of the treatment, lower IR-A, IR-B, and total IR mRNA expression in tumor tissue was significantly associated with longer PFS [IR-A: HR, 2.62 (P = 0.0062); IR-B: HR, 2.21 (P = 0.0202); and total IR: HR, 2.18 (P = 0.0230)] and OS [IR-A: HR, 2.94 (P = 0.0156); IR-B: HR, 2.69 (P = 0.0245); and total IR: HR, 2.72 (P = 0.0231)]. Conclusions: Cixutumumab (10 mg/kg) with or without antiestrogen q2w had an acceptable safety profile, but no significant clinical efficacy. Patients with low total IR, IR-A, and IR-B mRNA expression levels had significantly longer PFS and OS, independent of the treatment. The prognostic or predictive value of IR as a biomarker for IGF-1R–targeted therapies requires further validation. Clin Cancer Res; 22(2); 301–9. ©2015 AACR.
Risk for Carotid Intima–Medial Thickness in Recently Menopausal Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS): Determination Using Fuzzy Logic
Mordeson, John N. , Malik, D. S., Miller, Virginia M. , Jayachandran, Muthuvel , Shepherd, Alex J. , Budney, Sarah, Hunter, Larry W. , Shepherd, Alex

Mayo Clinic

New Mathematics and Natural Computation | August 27, 2015 | Volume: 11 | Issue: 03 | Pages: 267-283

10.1142/s179300571550009x Get It

Previously, the biological factors were weighed by the expert opinions. In this paper, we evaluate the risk factors proposed by the expert opinions. We use fuzzy logic techniques for predicting risk for development of carotid intima–medial thickness (CIMT) using expert opinion and various factors associated with CIMT in recently menopausal women. Study participants were enrolled in the Kronos Early Estrogen Prevention Study (KEEPS), a four-year study where participants were assigned to either oral or transdermal hormone treatments or to placebo. We use preference modeling techniques to determine the consensus winner of the causal factors. We use a measure to determine the degree to which one factor is preferred to another. We also determine the extent to which a factor is preferred to another by "most" experts. We determine the degree to which the experts agree. We consider a model concerning social networks and the effects of these networks on persons' opinions.
Improvements in Health Behaviors, Eating Self-Efficacy, and Goal-Setting Skills Following Participation in Wellness Coaching
Clark, Matthew M. , Bradley, Karleah L., Jenkins, Sarah M. , Mettler, Emily A., Larson, Brent G., Preston, Heather R., Liesinger, Juliette, Werneburg, Brooke L., Hagen, Philip T., Harris, Ann , Riley, Beth A., Olsen, Kerry D., Douglas, Kristin S. Vickers

Mayo Clinic

American Journal of Health Promotion | August 25, 2015 | Volume: 30 | Issue: 6 | Pages: 458-464

10.4278/ajhp.140627-qual-304 | PMID 26305609 Get It

Purpose: This project examined potential changes in health behaviors following wellness coaching. Design: In a single cohort study design, wellness coaching participants were recruited in 2011, data were collected through July 2012, and were analyzed through December 2013. Items in the study questionnaire used requested information about 11 health behaviors, self-efficacy for eating, and goalsetting skills. Setting: Worksite wellness center. Participants: One-hundred employee wellness center members with an average age of 42 years; 90% were female and most were overweight or obese. Intervention: Twelve weeks of in-person, one-on-one wellness coaching. Method: Participants completed study questionnaires when they started wellness coaching (baseline), after 12 weeks of wellness coaching, and at a 3-month follow-up. Results: From baseline to week 12, these 100 wellness coaching participants improved their self-reported health behaviors (11 domains, 0- to 10-point scale) from an average of 6.4 to 7.7 ( p < .001), eating selfefficacy from an average of 112 to 142 (on a 0- to 180-point scale; p < .001), and goal-setting skills from an average of 49 to 55 (on a 16- to 80-point scale; p < .001). Conclusion: These results suggest that participants improved their current health behaviors and learned skills for continued healthy living. Future studies that use randomized controlled trials are needed to establish causality for wellness coaching.
Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques
Monsell, Sarah E. , Kukull, Walter A. , Roher, Alex E., Maarouf, Chera L., Beach, Thomas G. , Caselli, Richard J. , Montine, Thomas J. , Reiman, Eric M. , Serrano, Geidy E.

Mayo Clinic

JAMA Neurology | August 24, 2015 | Volume: 72 | Issue: 10 | Pages: 1124

10.1001/jamaneurol.2015.1721 | PMID 26302353 Get It

Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
Espinel‐Ingroff, Ana , Carver, Peggy L. , Chen, S. C.-A., Eschenauer, Gregory , Getsinger, Diane, Govender, Nelesh P. , Grancini, Anna, Kidd, Sarah , Klinker, Kenneth , Kubin, Christine J. , Morris, Arthur J. , Peláez, Teresa, Quindós, Guillermo , Sánchez, F , Wengenack, Nancy L. , Solé, N. Borrell, Echeverría, J. , Esperalba, Juliana , Pedrosa, E. Gómez-G. de la, Linares, María José Pedraja, Marco, Francesc , Merino, Paloma , Pemán, Javier , Molino, Luisa Pérez del, Mayans, E. Roselló, Calvo, Carmen Rubio, Pipaón, Maite Ruiz Pérez de, Yagüe, Genoveva, García‐Effrón, Guillermo , Guinea, Jesús , Perlin, David S. , Sanguinetti, Maurizio , Shields, Ryan K. , Turnidge, John , Govender, N P , Quindós, G , Guinea, J , Álvarez-Fernández, Maximiliano , Cantón, Rafael , Chen, S. C.- A., González, Gloria María , Hanson, Kimberly E. , Kus, Julianne V. , Lockhart, Shawn R. , Meletiadis, Joseph , Rodríguez‐Iglesias, Manuel , Shoham, Shmuel , Pedrosa, Elia Gómez G. de la , García, Inmaculada García , Sánchez-Reus, F , Sanguinetti, M , Peman, J , Kidd, Sarah E

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 18, 2015 | Volume: 59 | Issue: 11 | Pages: 6725-6732

10.1128/aac.01250-15 | PMID 26282428 Get It

ABSTRACTNeither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established forCandidaspp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable.Candidaspecies wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007Candida albicans, 186C. dubliniensis, 3,188C. glabratacomplex, 119C. guilliermondii, 493C. krusei, 205C. lusitaniae, 3,136C. parapsilosiscomplex, and 1,016C. tropicalisisolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 μg/ml forC. albicans, 0.12, 0.25, and 0.03 μg/ml forC. glabratacomplex, 4, 2, and 4 μg/ml forC. parapsilosiscomplex, 0.5, 0.25, and 0.06 μg/ml forC. tropicalis, 0.25, 1, and 0.25 μg/ml forC. krusei, 0.25, 1, and 0.12 μg/ml forC. lusitaniae, 4, 2, and 2 μg/ml forC. guilliermondii, and 0.25, 0.25, and 0.12 μg/ml forC. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81Candidaisolates with identifiedfksmutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities ofCandidaspp. to caspofungin by reference methodologies is not recommended.
Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer
Psutka, Sarah P. , Boorjian, Stephen A. , Moynagh, Michael R., Schmit, Grant D. , Costello, Brian A. , Thompson, R. Houston, Stewart‐Merrill, Suzanne B., Lohse, Christine M. , Cheville, John C. , Leibovich, Bradley C. , Tollefson, Matthew K. , Psutka, Sarah P

Mayo Clinic

Journal of Urology | August 18, 2015 | Volume: 195 | Issue: 2 | Pages: 270-276

10.1016/j.juro.2015.08.072 | PMID 26292038 Get It